These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 17312113)
1. PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. Maier H; Isogawa M; Freeman GJ; Chisari FV J Immunol; 2007 Mar; 178(5):2714-20. PubMed ID: 17312113 [TBL] [Abstract][Full Text] [Related]
2. Blockade of PD-1/B7-H1 interaction restores effector CD8+ T cell responses in a hepatitis C virus core murine model. Lukens JR; Cruise MW; Lassen MG; Hahn YS J Immunol; 2008 Apr; 180(7):4875-84. PubMed ID: 18354211 [TBL] [Abstract][Full Text] [Related]
3. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503 [TBL] [Abstract][Full Text] [Related]
4. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Fisicaro P; Valdatta C; Massari M; Loggi E; Biasini E; Sacchelli L; Cavallo MC; Silini EM; Andreone P; Missale G; Ferrari C Gastroenterology; 2010 Feb; 138(2):682-93, 693.e1-4. PubMed ID: 19800335 [TBL] [Abstract][Full Text] [Related]
5. PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model. Tzeng HT; Tsai HF; Liao HJ; Lin YJ; Chen L; Chen PJ; Hsu PN PLoS One; 2012; 7(6):e39179. PubMed ID: 22761734 [TBL] [Abstract][Full Text] [Related]
6. Cutting Edge: Programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens. Martin-Orozco N; Wang YH; Yagita H; Dong C J Immunol; 2006 Dec; 177(12):8291-5. PubMed ID: 17142723 [TBL] [Abstract][Full Text] [Related]
7. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Okudaira K; Hokari R; Tsuzuki Y; Okada Y; Komoto S; Watanabe C; Kurihara C; Kawaguchi A; Nagao S; Azuma M; Yagita H; Miura S Int J Oncol; 2009 Oct; 35(4):741-9. PubMed ID: 19724910 [TBL] [Abstract][Full Text] [Related]
8. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. Yamazaki T; Akiba H; Koyanagi A; Azuma M; Yagita H; Okumura K J Immunol; 2005 Aug; 175(3):1586-92. PubMed ID: 16034097 [TBL] [Abstract][Full Text] [Related]
9. 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection. Vezys V; Penaloza-MacMaster P; Barber DL; Ha SJ; Konieczny B; Freeman GJ; Mittler RS; Ahmed R J Immunol; 2011 Aug; 187(4):1634-42. PubMed ID: 21742975 [TBL] [Abstract][Full Text] [Related]
10. PD-L1 upregulation by IFN-α/γ-mediated Stat1 suppresses anti-HBV T cell response. Liu L; Hou J; Xu Y; Qin L; Liu W; Zhang H; Li Y; Chen M; Deng M; Zhao B; Hu J; Zheng H; Li C; Meng S PLoS One; 2020; 15(7):e0228302. PubMed ID: 32628668 [TBL] [Abstract][Full Text] [Related]
12. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells. Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036 [TBL] [Abstract][Full Text] [Related]
13. Suppression of furin by interferon-γ and the impact on hepatitis B virus antigen biosynthesis in human hepatocytes. Wu JF; Hsu HY; Ni YH; Chen HL; Wu TC; Chang MH Am J Pathol; 2012 Jul; 181(1):19-25. PubMed ID: 22634051 [TBL] [Abstract][Full Text] [Related]
14. Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. Reynoso ED; Elpek KG; Francisco L; Bronson R; Bellemare-Pelletier A; Sharpe AH; Freeman GJ; Turley SJ J Immunol; 2009 Feb; 182(4):2102-12. PubMed ID: 19201863 [TBL] [Abstract][Full Text] [Related]
15. Blockade of endogenous B7-H1 suppresses antibacterial protection after primary Listeria monocytogenes infection. Seo SK; Jeong HY; Park SG; Lee SW; Choi IW; Chen L; Choi I Immunology; 2008 Jan; 123(1):90-9. PubMed ID: 17971153 [TBL] [Abstract][Full Text] [Related]
16. OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection. Jacobi FJ; Wild K; Smits M; Zoldan K; Csernalabics B; Flecken T; Lang J; Ehrenmann P; Emmerich F; Hofmann M; Thimme R; Neumann-Haefelin C; Boettler T J Hepatol; 2019 Jun; 70(6):1103-1113. PubMed ID: 30826436 [TBL] [Abstract][Full Text] [Related]
17. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714 [TBL] [Abstract][Full Text] [Related]
18. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Peng G; Li S; Wu W; Tan X; Chen Y; Chen Z Mol Immunol; 2008 Feb; 45(4):963-70. PubMed ID: 17868872 [TBL] [Abstract][Full Text] [Related]
19. Target-dependent B7-H1 regulation contributes to clearance of central nervous system infection and dampens morbidity. Phares TW; Ramakrishna C; Parra GI; Epstein A; Chen L; Atkinson R; Stohlman SA; Bergmann CC J Immunol; 2009 May; 182(9):5430-8. PubMed ID: 19380790 [TBL] [Abstract][Full Text] [Related]
20. IL-35 inhibits HBV antigen-specific IFN-γ-producing CTLs in vitro. Li X; Tian L; Dong Y; Zhu Q; Wang Y; Han W; Liu X; Ni Q; Chen Y; Li L Clin Sci (Lond); 2015 Sep; 129(5):395-404. PubMed ID: 25869609 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]